Skip to main content
. 2021 Nov 21;19:381. doi: 10.1186/s12951-021-01127-5

Fig. 5.

Fig. 5

PSN38@TPL-nsa antitumor efficiency in the CAFs-containing intraperitoneal tumor model. a Establishment of CAFs-containing intraperitoneal tumor model and schedule of in vivo antitumor experiments. b In vivo bioluminescence imaging of the mice after intravenous injections of PBS, TPL-nsa, PSN38, PSN38 + TPL-nsa and PSN38@TPL-nsa (n = 4). White dotted lines and arrows indicated the tumor nodules. c Quantitative analysis of bioluminescence imaging intensity on Day 12. d Body weight variation in the tumor-bearing mice during the experimental period (n = 4). e Western blotting analysis of PARP, caspase-3 and BAX family proteins of tumors in the different groups at the end of experiments. f Dissected intraperitoneal tumor nodules after humanitarian execution (n = 4). g, h The intraperitoneal tumor weights (g) and nodule numbers (h) in each group were statistically analyzed. All data are presented as mean ± SD. Unpaired Student’s t-test was used to analyze the data. (*p < 0.05; **p < 0.01; ***p < 0.001)